Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,642 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider David Michael Clark sold 25,642 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $14.17, for a total value of $363,347.14. Following the completion of the transaction, the insider directly owned 245,690 shares in the company, valued at approximately $3,481,427.30. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Michael Clark also recently made the following trade(s):

• On Monday, December 15th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $11.00, for a total value of $282,073.00.
• On Monday, November 24th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30.
• On Tuesday, November 4th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock remained flat at $14.21 during trading on Tuesday. 17,892,963 shares of the company traded hands, compared to its average volume of 5,234,081. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The firm’s 50-day simple moving average is $9.60 and its 200-day simple moving average is $7.91. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $14.36. The company has a market cap of $4.38 billion, a PE ratio of -355.16 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. During the same quarter in the previous year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. TD Cowen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price on the stock. in a research note on Monday. JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Citigroup reissued a “neutral” rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $15.81.

Key Amicus Therapeutics News

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: Report that BioMarin is pursuing a roughly $4.8 billion acquisition of Amicus — a buyout at a meaningful premium would be the most bullish catalyst and could push FOLD substantially higher if confirmed. A $4.8 Billion Reason to Buy BioMarin Stock Today
• Positive Sentiment: Technical strength: Amicus reportedly cleared a key benchmark and hit a 90-plus relative strength (RS) rating — this suggests strong momentum and may attract technical buyers. Amicus Therapeutics clears key benchmark, hitting 90-plus RS rating
• Neutral Sentiment: Analysts’ price targets clustered near $14.50 — only about ~2% above current levels — implying limited near-term upside even before considering deal risk or timing. Benzinga coverage
• Negative Sentiment: Citigroup downgraded Amicus from “strong-buy” to “hold” and lowered its price target (previously $17 → $14.50), signaling reduced conviction from a major broker and likely weighing on sentiment. Citigroup downgrades Amicus Therapeutics (FOLD) Zacks report
• Negative Sentiment: TD Cowen cut its rating from “buy” to “hold” and set a $14.50 target, another downgrade that reduces the analyst-driven bullish case. Finviz coverage Zacks

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of FOLD. Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 29,534,029 shares of the biopharmaceutical company’s stock worth $232,728,000 after purchasing an additional 126,441 shares in the last quarter. William Blair Investment Management LLC increased its stake in Amicus Therapeutics by 7.6% during the 3rd quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock worth $124,104,000 after buying an additional 1,107,083 shares during the period. Vestal Point Capital LP lifted its holdings in Amicus Therapeutics by 178.4% during the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after buying an additional 7,625,000 shares in the last quarter. State Street Corp boosted its position in Amicus Therapeutics by 21.5% in the 2nd quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after buying an additional 2,049,078 shares during the period. Finally, Redmile Group LLC grew its stake in shares of Amicus Therapeutics by 35.1% in the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after acquiring an additional 2,478,779 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.